FK866 (APO866): Precision NAMPT Inhibitor for Hematologic Cancer Research

Executive Summary: FK866 (APO866) is a non-competitive inhibitor of NAMPT with picomolar potency (Ki = 0.4 nM), targeting NAD biosynthesis in cancer cells [APExBIO product]. It induces selective, caspase-independent cell death in AML models by depleting NAD and ATP (Ji et al. 2025). FK866 spares normal human hematopoietic progenitor cells, supporting its utility in precision cancer metabolism research. The compound demonstrates strong in vivo antitumor activity, including tumor growth inhibition in AML and lymphoblastic lymphoma mouse xenografts. FK866 is recommended for short-term solution use, is insoluble in water, and is available as a solid for research workflows.

Biological Rationale

Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in the NAD salvage pathway. NAD is essential for metabolic flux and energy production in both normal and malignant cells. Cancer cells, particularly hematologic malignancies, are highly dependent on NAD biosynthesis for survival and proliferation (Ji et al. 2025). Inhibiting NAMPT leads to intracellular NAD and ATP depletion, disrupting metabolic homeostasis and selectively targeting cancer metabolism [see review]. Acute myeloid leukemia (AML) models are especially sensitive to NAD deprivation. FK866 (APO866) is designed to exploit this metabolic vulnerability.

Mechanism of Action of FK866 (APO866)

FK866 (APO866) is a highly specific, non-competitive NAMPT inhibitor. It binds NAMPT and blocks the conversion of nicotinamide to nicotinamide mononucleotide (NMN), a precursor for NAD synthesis. Potency is documented with Ki values of 0.4 nM and IC₅₀ values from 0.09 nM to 27.2 nM in cell-based assays [APExBIO]. NAD depletion leads to a rapid decline in ATP levels. This metabolic collapse triggers cell death via a caspase-independent pathway. FK866 induces mitochondrial membrane depolarization, disrupting mitochondrial function. Autophagy is promoted, reliant on de novo protein synthesis. Notably, FK866 spares normal human hematopoietic progenitor cells, offering a therapeutic window for selective cytotoxicity in cancer cells [review].

Evidence & Benchmarks

• FK866 demonstrates a Ki of 0.4 nM against NAMPT in vitro (APExBIO, product data).
• IC₅₀ values for FK866 range from 0.09 nM to 27.2 nM in hematologic cancer cell lines (APExBIO, product data).
• FK866 induces depletion of NAD and ATP, resulting in selective cytotoxicity in acute myeloid leukemia (AML) cells, but not in normal hematopoietic progenitor cells (Ji et al. 2025, DOI:10.3390/ph18101503).
• Cell death is caspase-independent and involves mitochondrial membrane depolarization and autophagy (Ji et al. 2025, DOI:10.3390/ph18101503).
• In vivo, FK866 prevents tumor growth and improves survival in mouse xenograft models of AML and lymphoblastic lymphoma (APExBIO, product page).
• FK866 is insoluble in water but soluble in DMSO (≥19.6 mg/mL) and ethanol (≥49.6 mg/mL) (APExBIO, specification).

For an in-depth mechanistic review, see "FK866 (APO866): Precision NAMPT Inhibition and the Future...", which focuses on translational applications beyond AML. This article updates those findings with newly verified quantitative benchmarks and workflow parameters.

Applications, Limits & Misconceptions

FK866 (APO866) is widely used in:

• Hematologic cancer research, especially AML and lymphoblastic lymphoma.
• Studies on cancer metabolism and NAD biosynthesis inhibition.
• Models investigating caspase-independent cell death and mitochondrial function.
• Evaluation of therapeutic windows between malignant and normal progenitor cells.

Related mechanistic insights are available in "FK866 (APO866): NAMPT Inhibition and Mitochondrial Dynami...", which details mitochondrial membrane depolarization. The current article extends those findings by clarifying cell-selectivity and workflow integration parameters.

Common Pitfalls or Misconceptions

• FK866 is not effective in cell types with alternative NAD biosynthesis pathways (e.g., cells with high Preiss–Handler pathway activity).
• It does not induce classic caspase-dependent apoptosis; inappropriate use of apoptosis markers may yield misleading interpretations.
• FK866's cytotoxicity is not universal for all cancer types; solid tumor models may show variable sensitivity.
• Stock solutions must be stored at -20°C; prolonged exposure to room temperature or repeated freeze-thaw cycles can degrade activity.
• FK866 is insoluble in water; improper solvent selection leads to precipitation and loss of potency.

For further benchmarking, see "FK866 (APO866): Potent Non-Competitive NAMPT Inhibitor fo...", which provides comparative potency data and highlights selectivity in AML models. This article updates those claims with new evidence from recent peer-reviewed literature.

Workflow Integration & Parameters

• FK866 (APO866) is supplied as a solid (C24H29N3O2) by APExBIO; SKU: A4381 [product page].
• Solubility: DMSO (≥19.6 mg/mL), ethanol (≥49.6 mg/mL). Not soluble in water. Prepare fresh solutions for short-term use.
• Storage: Store powder at -20°C; stock solutions below -20°C for several months.
• Typical in vitro working concentrations: 1–50 nM, depending on cell line sensitivity.
• Monitor NAD and ATP depletion via standard colorimetric or luminescent assays.
• For xenograft studies: Dose and administration schedules should be optimized as per published in vivo protocols (Ji et al. 2025).

Conclusion & Outlook

FK866 (APO866) is a validated, highly selective NAMPT inhibitor suitable for dissecting cancer metabolism and cell death pathways, especially in hematologic malignancies. Its non-competitive mechanism, high potency, and selective cytotoxicity make it a gold standard reagent for NAD biosynthesis inhibition studies. APExBIO provides reliable sourcing and technical support for research-grade FK866 (A4381). Ongoing research may expand its applications in vascular aging and other NAD-dependent disease models, as highlighted by recent findings on the NAMPT/PARP1 axis (Ji et al. 2025).